Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep 19;9(9):180.
doi: 10.1038/s41424-018-0049-9.

Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis

Affiliations
Free PMC article
Review

Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis

Haritha G Reddy et al. Clin Transl Gastroenterol. .
Free PMC article

Erratum in

Abstract

Immune checkpoint inhibitors (ICPIs) are monoclonal antibodies that target downregulators of the anti-cancer immune response: cytotoxic T-lymphocyte antigen-4, programmed cell death protein-1, and its ligand PD-L1. ICPIs are now approved for the treatment of a wide array of malignancies, with rates of durable responses in the metastatic setting far exceeding what would be expected from conventional chemotherapy. ICPIs have also been associated with rare but serious immune-related adverse events due to over-activation of the immune system that can affect any organ, including the gastrointestinal tract and liver. As the use of ICPIs in oncology continues to increase, ICPI-associated colitis and hepatitis will be encountered frequently by gastroenterologists and hepatologists. This review will focus on the diagnosis and management of ICPI-associated colitis and hepatitis. We will also compare these ICPI-related toxicities with sporadic inflammatory bowel disease and autoimmune liver disease.

Conflict of interest statement

Competing interests

Guarantor of the article: Andrew W. Tai, MD, PhD.

Specific authors’ contributions: Planning the manuscript: HGR, BJS, and AWT. Drafting and editing the manuscript: HGR, BJS, and AWT. All authors have approved the final submitted draft.

Potential competing interests

BJS: Research support from: Genentech, OncoMed, Incyte, and Bristol-Meyers Squibb.

Figures

Fig. 1
Fig. 1
This flow diagram depicts a basic approach for evaluation and management of a patient with suspected ICPI colitis based on the severity of their symptoms as defined by Common Terminology Criteria for Adverse Events v5.0
Fig. 2
Fig. 2
This flow diagram depicts a basic approach for evaluation and management of a patient with suspected ICPI hepatitis based on the severity of their symptoms as defined by Common Terminology Criteria for Adverse Events v5.0

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018;68:7–30. doi: 10.3322/caac.21442. - DOI - PubMed
    1. Gupta A, et al. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment. Pharmacol. Ther. 2015;42:406–417. doi: 10.1111/apt.13281. - DOI - PubMed
    1. Alsaab HO, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front. Pharmacol. 2017;8:561. doi: 10.3389/fphar.2017.00561. - DOI - PMC - PubMed
    1. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. New Engl. J. Med. 2018;378:158–168. doi: 10.1056/NEJMra1703481. - DOI - PubMed
    1. National Cancer Institute. Common Terminology Criteria for Adverse Events v5.0. November 27, (2017).

Publication types

MeSH terms

Feedback